Zoetis Inc. (ZTS) has shown strong performance as it surpasses estimates for its Q3 2024 earnings and raised its annual forecasts, driven by robust pet treatment demand. Notably, the company is expected to participate in the upcoming Jefferies London Healthcare Conference. Several groups including the Principal Financial Group Inc. have increased their investment in Zoetis. The company's Q3 earnings and revenues exceeded estimates, with strategic divestitures also highlighted—promising news for potential investors. Zoetis' new Vetscan OptiCell offering has sparked intrigue in market growth, while its Q3 earnings showcased soaring earnings, fresh market captures, and an uptick on the outlook for 2024. Furthermore, a robust quarterly dividend of $0.432 was declared. However, despite these positive developments, Zoetis' stocks did slump and the William Blair puts out a negative outlook for the company's earnings. While there have been concerns about arthritis drugs impacting pets, investors still view Zoetis favorably due to earnings growth and its proactive strategies.
Zoetis ZTS News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Fri, 08 Nov 2024 00:11:34 GMT -
Rating 8
- Innovation 6
- Rumor -2
